(Q42144156)

17 October 2017

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features (English)

1 reference

chronic lymphocytic leukemia

17 October 2017

0 references

1 reference

1 reference

5

K A Blum

1 reference

17 October 2017

J A Woyach

1

1 reference

17 October 2017

G Lozanski

2

1 reference

17 October 2017

A S Ruppert

3

1 reference

17 October 2017

A Lozanski

4

1 reference

17 October 2017

J A Jones

6

1 reference

17 October 2017

J M Flynn

7

1 reference

17 October 2017

A J Johnson

8

1 reference

17 October 2017

M R Grever

9

1 reference

17 October 2017

N A Heerema

10

1 reference

17 October 2017

J C Byrd

11

1 reference

17 October 2017

13 January 2012

1 reference

17 October 2017

1 reference

17 October 2017

26

1 reference

17 October 2017

6

1 reference

17 October 2017

1442-1444

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2011.375

17 October 2017

0 references

cites work

TP53 mutation and survival in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675648

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675648

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675648

Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675648

Genomic aberrations and survival in chronic lymphocytic leukemia

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675648

Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675648

The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675648

Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675648

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675648

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3675648

Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications

17 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2011.375

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2011.375

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2011.375

Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma

21 January 2018

1 reference

12 December 2020

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

1 reference

12 December 2020

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

1 reference

12 December 2020

Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2011.375

1 reference

Dimensions Publication ID

17 October 2017

1011084459

0 references

Fatcat ID

release_avlaczzgxve4bjq7goh74dzuci

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/avlaczzgxve4bjq7goh74dzuci

24 November 2022

mapped directly with Wikidata item

1 reference

17 October 2017

PubMed publication ID

22289993

1 reference